AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance

Key Points

• AngioDynamics issued FY 2027 guidance for EPS of -$0.29 to -$0.24 and revenue of $336 million to $341 million, broadly aligning with analyst expectations.
• The company’s latest quarter surpassed estimates, reporting EPS of -$0.07 versus the expected -$0.11 and revenue of $86.61 million compared with the $80.24 million consensus.
• Analyst sentiment is moderately bullish, with an average price target of $19.50; however, shares fell 1.6% to open at $14.19, and an executive recently sold 23,370 shares.

AngioDynamics (NASDAQ:ANGO - Get Free Report) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of -0.290--0.240 for the period, compared to the consensus EPS estimate of -0.260. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $337.6 million.

AngioDynamics Trading Down 1.6%

Shares of NASDAQ ANGO opened at $14.19 on Thursday. The firm has a market cap of $596.69 million, a P/E ratio of -16.31 and a beta of 0.30. The business's 50 day moving average is $15.46 and its 200-day moving average is $13.11. AngioDynamics has a 1-year low of $9.39 and a 1-year high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analysts' expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Analysts forecast that AngioDynamics will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on ANGO. Zacks Research upgraded shares of AngioDynamics from a "strong sell" rating to a "hold" rating in a research report on Monday. Canaccord Genuity Group upped their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Wall Street Zen raised shares of AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 22nd. HC Wainwright upped their target price on AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $19.50.

Insider Transactions at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of the business's stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 6.00% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company's portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.